Tirzepatide is the first-in-class dual GIP/GLP-1 receptor agonist “twincretin” simultaneously activating GIPR and GLP-1R. CAS: 2023788-19-2 | MW: 4,813.5 Da | Half-life: ~5 days. C20 fatty diacid-conjugated peptide with albumin binding for extended half-life. Supplied as lyophilised peptide at ≥98% purity for preclinical metabolic and incretin biology research.

Research Background

Tirzepatide was developed by Eli Lilly as the first dual agonist of the incretin receptor system. Phase 3 clinical data (SURPASS programme) demonstrated robust glycaemic and body composition effects, generating extensive mechanistic research interest. The C20 fatty diacid conjugation provides albumin binding for the ~5-day half-life relevant to weekly dosing in clinical contexts and infrequent dosing intervals in animal model experiments.

Mechanism of Action & Research Applications

• GLP-1R signalling: Gs/cAMP/PKA pathway in beta-cells driving glucose-dependent insulin secretion; glucagon suppression; delayed gastric emptying; hypothalamic satiety signalling
• GIPR signalling: Complementary insulin secretion; adipocyte effects (lipolysis modulation); independent central food intake effects observed in rodent studies
• Synergistic interactions: Greater metabolic effects than either receptor alone, through complementary intracellular signalling amplification and beta-cell sensitisation

Storage & Handling

• Long-term storage: -20°C (lyophilised stable 18-24 months)
• Short-term storage: 2-8°C for up to 3 weeks after reconstitution
• Reconstitution: Sterile bacteriostatic water; dissolve by gentle swirling; ensure complete dissolution (fatty acid conjugation reduces solubility vs unmodified peptides)
• Handling: Aliquot; avoid repeated freeze-thaw; standard peptide precautions

Related Research Compounds

Comparative triple agonist: Retatrutide 20mg and Retatrutide 10mg. Hormonal context: Kisspeptin 5mg.

Frequently Asked Questions

Q: What is Tirzepatide?

A: Tirzepatide is a dual GIP/GLP-1 receptor agonist (CAS 2023788-19-2, MW 4,813.5 Da, ~5-day half-life) used in preclinical research to study incretin signalling, glycaemic regulation, and adipose biology. For laboratory research use only.

Q: How is Tirzepatide typically used in research?

A: Reconstituted in sterile bacteriostatic water and used in animal metabolic models or cell-based receptor pharmacology assays for dose-response studies, dual receptor agonism characterisation, and beta-cell or adipose tissue biology investigations.

Q: What is the storage recommendation for Tirzepatide?

A: -20°C lyophilised (18-24 months). Reconstituted: 2-8°C up to 3 weeks. Aliquot. Fatty acid conjugation reduces solubility vs unmodified peptides – ensure complete dissolution before use.

Q: What purity and form is Tirzepatide supplied in?

A: Lyophilised powder at ≥98% purity. 20mg per vial.

For research use only. Not for human or animal consumption. Not a medicinal product.